Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.41)
# 4,227
Out of 5,090 analysts
5
Total ratings
40%
Success rate
-28.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNTI Senti Biosciences | Initiates: Outperform | $6 | $2.13 | +181.69% | 1 | Nov 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $16.51 | +451.18% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $4.22 | +184.36% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $99.72 | +12.31% | 1 | Oct 28, 2022 |
Senti Biosciences
Nov 21, 2025
Initiates: Outperform
Price Target: $6
Current: $2.13
Upside: +181.69%
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $16.51
Upside: +451.18%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $4.22
Upside: +184.36%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $99.72
Upside: +12.31%